Lastly, a chimeric antigen receptor (CAR) T-cell therapy, targeting several antigens (e.g. MSLN, MUC1, NY-ESO-1, GPC3, PSCA, EGFR, ROR1, HER2, PDL1) with limited expression in normal tissues but high and/or specific expression in tumor cells, is presently being tested against NSCLC31. This evidence concerns the gene CD274 and neoplasm.